Skip 
Navigation Link
Medical Disorders
Resources
Basic InformationLookupsLatest News
Black Children Missing Out on Eczema TreatmentNew Framework Guides Tx Decisions for Atopic DermatitisHealth Tip: Recognizing SepsisAround the World, Too Little Relief for PainNearly 4 in 10 U.S. Adults Now ObeseFDA Panel Supports Gene Therapy for Kids With Rare Eye Disease30-Day Mortality Lower With Female SurgeonsDirect Primary Care May Fill Niche for Uninsured3 Factors That Could Raise Your Risk of Bloodstream InfectionStroke Risk Factors Are RisingTwo Ebola Vaccines Spur Lasting Immune ResponseHormone Therapy May Be OK for Women With MigrainesMigraine MattersMedial Temporal Lobe Surgery Linked to Prevalence of TinnitusHigher Levels of Fungus ID'd in Patients With Crohn'sWhere There's Type 1 Diabetes, Celiac Disease May FollowAntibiotic Use Not Linked to Islet, Celiac Disease AutoimmunitySome U.S. Olympians Got West Nile in Brazil, But Not ZikaPenicillin Misconceptions May Raise Post-Op Infection RiskHate UTIs? One Simple Step Can Cut the RiskIDSA: Retail Meat May Be a Transmission Source for UTIsLonger Anesthesia Duration Tied to More Surgical ComplicationsFirst Test to Detect Zika in Blood Donations ApprovedHealth Tip: Learn Symptoms of Childhood SinusitisLimiting 'Cold Time' Could Make More Organs Available for TransplantHealth Literacy Linked to Length of Stay After Abdominal SurgeryZika Vaccine Works in Early Human TrialHealth Tip: Understanding Loud Noise and Hearing LossAllergy Relief Do's and Don'tsPatient Factors Differ for Surgical, All-Cause ReadmissionComing Soon: A Faster Test for Antibiotics Against UTIs?Antibody Injections in Pregnancy Might Shield Fetus From ZikaHealth Tip: Giving BloodMore U.S. Measles Cases From No Vaccine vs. Imported DiseaseHigh Epsom Salt Intake Can Lead to Severe Liver InjuryTattoo Pigment Hypersensitivity Can Mimic LymphomaObesity Linked to 13 Types of CancerBlood Thinners Can Come With Dangerous Side EffectsMeasles Making a Comeback in the United StatesAfter Deepwater Oil Cleanup in Gulf, Ill Effects PersistState Laws Can Promote Hepatitis C Virus ScreeningHow Much Alcohol Is Really OK?Girls' Sports-Related Concussions May Last Twice As LongSingle Mutation Made Zika Virus More VirulentVi-Tetanus Toxoid Conjugate Vaccine Can Prevent TyphoidDialysis Patients Often End Up Back in the HospitalRespiratory Disease Death Rates Have SoaredGenetic Tweaks in Mosquitoes Might Curb Malaria TransmissionImmunochromatography Testing Differentiates Dengue, ZikaFDA Approves New Continuous Glucose Monitor for Diabetes
Questions and AnswersLinksBook Reviews
Related Topics

Three-Drug Combo Pill Nearly 100 Percent Effective in Curing Hep C


HealthDay News
Updated: Jun 1st 2017

new article illustration

THURSDAY, June 1, 2017 (HealthDay News) -- A pill containing the antiviral drugs sofosbuvir, velpatasvir, and voxilaprevir is nearly 100 percent effective in curing hepatitis C in patients whose disease returned after treatment with direct-acting antiviral agents, according to research published in the June 1 issue of the New England Journal of Medicine.

In two phase 3 trials, Marc Bourlière, M.D., from the Hospital Saint Joseph in Marseilles, France, and colleagues treated patients with the combination pill or a placebo or other antiviral drugs. In the first trial, 300 patients were randomly assigned to either the combination pill or a placebo (150 patients in each group). These patients all had hepatitis C genotype 1. In addition, 114 patients with other genotypes of hepatitis C were given the combination pill. Patients took the pill daily for 12 weeks. Among patients taking the combination pill, 96 percent responded to treatment. None on the placebo showed a response, the researchers found.

The second trial included 314 patients with hepatitis C genotypes 1, 2 or 3. All had failed other treatments, but hadn't been given a NS5A inhibitor, such as velpatasvir or daclatasvir. This group received either the combination pill (163 patients) or sofosbuvir-velpatasvir (151 patients). In addition, 19 patients with genotype 4 hepatitis C were given the combination pill. In this trial, 98 percent of the patients taking the combination pill responded to 12 weeks of treatment. And 90 percent of those who received sofosbuvir-velpatasvir responded to treatment, the investigators found.

The most common side effects were headache, fatigue, diarrhea, and nausea. Only 1 percent or fewer patients stopped treatment because of the side effects. This new pill is being developed as a rescue treatment for patients who have failed other therapy, Bourlière told HealthDay. When it was used as an initial treatment in another study, the combination pill fared no better than the usual treatment, he said.

The study was funded by Gilead Sciences, the manufacturer of the combination pill.

Abstract/Full Text (subscription or payment may be required)